Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
Author:
Affiliation:
1. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
2. Sheba Medical Center, Ramat Gan, Israel
3. Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
Publisher
American Medical Association (AMA)
Subject
Oncology,Cancer Research
Link
https://jamanetwork.com/journals/jamaoncology/articlepdf/2765288/jamaoncology_bomze_2020_le_200017.pdf
Reference5 articles.
1. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis.;Duan;JAMA Oncol,2020
2. Deviation from the proportional hazards assumption in randomized phase 3 clinical trials in oncology: prevalence, associated factors, and implications.;Rahman;Clin Cancer Res,2019
3. Reconstructing time-to-event data from published Kaplan-Meier curves.;Wei;Stata J,2017
4. Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio.;Pak;JAMA Oncol,2017
5. Restricted mean survival time: an obligatory end point for time-to-event analysis in cancer trials?;A’Hern;J Clin Oncol,2016
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. An overview: Management of patients with advanced hepatocellular carcinoma;BioScience Trends;2022-12-25
2. Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology;Journal of Translational Medicine;2022-12-13
3. Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy;The Lancet Oncology;2022-06
4. Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma;JAMA Network Open;2022-03-09
5. Revealing Sulfur Dioxide Regulation to Nucleophagy in Embryo Development by an Adaptive Coloration Probe;Analytical Chemistry;2021-09-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3